DIA EUROPE – ADaM Specifications for Statistical Reporting: Making Documentation Almost Fun
On March 17, IDDI is participating at DIA Europe. Jean-Christophe Chiem, PhD, Senior Statistical Scientist at IDDI, will be sharing…
News
News
Discover the news of an experienced Contract Research Organization specialized in Biostatistics and eClinical services to optimize your clinical trials.
Seminar: Missing data. Should I care?
February 26, 2021
Presenter: Vaiva Deltuvaite-Thomas, Research Statistician at IDDIDate and Time: 26 February, 14:30 – 15:30 CETLocation: Via TEAMS ABSTRACT Most of the…
Looking back, thinking ahead: industry leaders talk trends
Experts from our industry share their thoughts on 2020 and what trends we may expect in 2021. IDDI’s Chief Commercial…
Happy Holiday Season from the IDDI Team
Happy Holiday season from the IDDI team and thank you for all your support throughout the year. Wishing you a…
Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer
Improvements in the treatment of patients with cancer largely depend on clinical trials comparing a new intervention with a previous…
2021 Year in Preview: The Year to Come and the Year That Was
Recently, Serge Bodart, our Chief Commercial Officer, shared his insights in PharmaVOICE – Nov./Dec. 2020 on the challenges and opportunities this…
IDDI Supporting Cancer Charity Associations
IDDI’s Mission to Giving Thanks this Season The Thanksgiving season is the perfect time to thank, support and help those…
NEWSLETTER NOVEMBER 2020
NEWSLETTERNOVEMBER 2020CLINICAL TRIAL NEWS BREAKFAST WEBINAR : DRUG DEVELOPMENT IN ONCOLOGY IN THE ERA OF PRECISION MEDICINE 19th NOVEMBER, 2020…
Epidemiology, Methodology, and Clinical Research in the midst of the COVID-19 pandemic
Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country…
IDDI at Biomarker and Companion Diagnostics Virtual Conference
October 20, 2020 — October 23, 2020
Leveraging next gen technologies beyond conventional biomarker drug discovery The emergence of the need for safety and efficacy of a…